These findings support the idea that GPX4 may confer a survival advantage on DLBCL cells, possibly through oxidant tolerance and decreased sensitivity to ferroptosis, and that inhibition of GPX4 may represent a potential therapeutic target for patients with high-risk DLBCL disease. The gene discussed is GPX4; the disease is diffuse large B-cell lymphoma.